Abstract

Novel KRAS-targeted therapies unlocked new treatment options for previously untreatable patients. However, in colorectal cancer (CRC), resistance to KRAS-targeted therapy develops rapidly, making it imperative to understand its underlying mechanisms. Cancer-associated fibroblasts (CAFs) induce therapy resistance by generating and maintaining cancer stem cells (CSCs). Additionally, CAFs secretome can modulate KRAS mutant CRC cells proteomic profile, independently of mutant KRAS. Hence, we investigated whether CAF-derived factors could induce resistance to KRAS inhibition by promoting a KRAS-independent stem-like phenotype. Evaluation of KRAS-mutant CRC cell lines (HCT15, HCT116, and SW480) revealed unique basal stem cell marker expression levels. Silencing KRAS lead to up-regulation of CD24, down- regulation of CD49f and CD104, and reduced stemness. However, CAF-secreted factors attenuated these effects, restoring stem cell markers expression and increasing stemness. RNA sequencing showed that CAF-secreted factors upregulate pro-tumorigenic pathways in KRAS-silenced cells, including cell cycle control, epithelial-mesenchymal transition (EMT), NOTCH, and immune regulation, leading to increased cell cycling and exit from quiescence. Overall, we provide mechanistic insights illuminating the role of fibroblasts in counteracting KRAS silencing-induced growth inhibition and enhancing stemness. Our results show that the limited success of KRAS-targeted therapies is not only derived from cell-intrinsic factors but also dependent on external factors derived from the tumor microenvironment, thus opening avenues to improve therapy responses in CRC.